Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy OptionsBusiness Wire • 06/28/21
Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma PatientsBenzinga • 06/28/21
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell LymphomaBusiness Wire • 06/28/21
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 WeeksBusiness Wire • 06/24/21
Gilead (GILD) Veklury Data Positive in Hospitalized COVID PatientsZacks Investment Research • 06/22/21
Gilead says real-world data shows COVID-19 drug Veklury can reduce the risk of deathMarket Watch • 06/21/21
Gilead's Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data SetsBusiness Wire • 06/21/21
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021Business Wire • 06/21/21
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 06/17/21
Gilead's Kite Pharma Collaborates With Shoreline Biosciences For Cell Therapies For Cancer SettingsBenzinga • 06/17/21
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell TherapiesBusiness Wire • 06/17/21
Longer-term Data for Kite's Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative AnalysisBusiness Wire • 06/12/21